Compare PZG & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PZG | PMN |
|---|---|---|
| Founded | 1992 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Metal Mining | Pharmaceuticals and Biotechnology |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.0M | 84.1M |
| IPO Year | 2015 | 2022 |
| Metric | PZG | PMN |
|---|---|---|
| Price | $0.94 | $3.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $42.25 |
| AVG Volume (30 Days) | 265.9K | ★ 377.2K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $330,259.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.88 | $0.29 |
| 52 Week High | $2.70 | $27.40 |
| Indicator | PZG | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 30.28 |
| Support Level | $0.88 | $2.78 |
| Resistance Level | $1.06 | $15.05 |
| Average True Range (ATR) | 0.07 | 1.07 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 37.86 | 6.01 |
Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold and Bald Peak Project.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.